# CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT

> **NCT01760811** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Rabin Medical Center** · enrollment: 25 (estimated)

## Conditions studied

- Squamous Cell Carcinoma

## Interventions

- **DRUG:** Erbitux,merck serono

## Key facts

- **NCT ID:** NCT01760811
- **Lead sponsor:** Rabin Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-01
- **Primary completion:** 2015-12
- **Final completion:** 2017-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2013-01-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01760811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01760811, "CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01760811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*